Arcus Biosciences, Inc. Banner Image

Arcus Biosciences, Inc. has reached its limit for free report views

Work for Arcus Biosciences, Inc.? Upgrade Your Profile and unlock all your annual reports.

Arcus Biosciences, Inc.

  • Ticker RCUS
    Exchange NYSE More
  • Industry Biotechnology More
  • Sector Healthcare More
Arcus Biosciences, Inc. Logo Image
  • 51-200 Employees
  • Based in Hayward, California
Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs. AB928, the first and only dual A2a/A2b adenosine receptor antagonist in the clinic, is being evaluated in several Phase 1b/2 studies acrossMore multiple indications, including prostate, colorectal, non-small cell lung, pancreatic, triple-negative breast and renal cell cancers. AB680, the first small-molecule CD73 inhibitor in the clinic, is in Phase 1 development for first-line treatment of metastatic pancreatic cancer. AB154, an anti-TIGIT monoclonal antibody, is in Phase 2 development for first-line treatment of metastatic non-small cell lung cancer in combination with zimberelimab and AB928. Zimberelimab (AB122), Arcus’s anti-PD1 monoclonal antibody, is being evaluated in a Phase 1b study as monotherapy for cancers with no approved anti-PD1 treatment options, as well as in combinations across the portfolio.
Arcus Biosciences, Inc.

Most Recent Annual Report

Arcus Biosciences, Inc. MOST RECENT 2019 Annual Report and Form 10K

Report Locked. Arcus Biosciences, Inc. has reached its limit for free report views.

Older/Archived Annual Reports